BioTuesdays

Tag - AFIB

Acutes-Medical-Logo

BTIG cuts Acutus Medical to neutral from buy

BTIG downgraded Acutus Medical (NASDAQ:AFIB) to “neutral” from “buy” and removed its price target, citing a forecast of flat sales in 2022, among other things. The stock closed at $2.46 on Jan. 19. Acutus is a cardiac...

Acutes-Medical-Logo

Canaccord cuts Acutus Medical to hold; PT to $3

Canaccord Genuity downgraded Acutus Medical (NASDAQ:AFIB) to “hold” from “buy” and slashed its price target to $3 from $10, citing a financing/dilution risk. The stock closed at $3.02 on Jan. 13. Acutus is an arrhythmia...

Acutes-Medical-Logo

Analysts cut Acutus Medical PT to $8 and $10

Analysts for BTIG and Canaccord Genuity reduced their price targets for Acutus Medical (NASDAQ:AFIB) to $8 from $20 and to $10 from $18, respectively, but maintain their “buy” ratings, after the company reported third...

Acutes-Medical-Logo

WB cuts Acutus Medical to market perform

William Blair downgraded Acutus Medical (NASDAQ:AFIB) to “market perform,” saying “early-stage growing pains lead to lower than expected guidance.” The stock closed at $16.83, down $2.23, on March 18. Analyst Margaret...

Acutes-Medical-Logo

FDA clears Acutus’ AcQMap catheter

The FDA cleared Acutus Medical’s (NASDAQ:AFIB) AcQMap, a 3D mapping and navigation catheter designed to be inserted into the left and right atrium. In addition to cardiac activation mapping, the AcQMap catheter can...

Acutes-Medical-Logo

Analysts start Acutus Medical at hold, buy, OP

Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Acutus Medical (NASDAQ:AFIB) with “hold”, “buy” and “outperform” ratings, respectively.  Acutus is a pure-play electrophysiology company...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.